• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

13.40 -0.03 (-0.22%)
Official Closing Price Updated: 6:30 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
Today 13:47 EDT
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Today 7:30 EDT
From Organon & Co.
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders
June 16, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)
June 16, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
June 10, 2026
From Organon & Co.
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders
June 09, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)
June 09, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Organon to Present New Research on Access and Value at ISPOR 2026
May 15, 2026
From Organon & Co.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
May 14, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
May 06, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
May 05, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders
May 05, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether AVNS, OGN, ESQ, VRE are Obtaining Fair Deals for their Shareholders
May 05, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2026
April 30, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Cancels First Quarter Earnings Call
April 29, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN
April 28, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
April 27, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders
April 27, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Sun Pharma signs Definitive Agreement to Acquire Organon
April 26, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
April 16, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
April 15, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
March 27, 2026
From Organon & Co.
Via Business Wire
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 27, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
February 23, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
February 12, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
January 29, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Completes Divestiture of JADA® System to Laborie
January 28, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
January 16, 2026
From Organon & Co.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap